Hostname: page-component-5c6d5d7d68-vt8vv Total loading time: 0.001 Render date: 2024-08-08T06:49:09.892Z Has data issue: false hasContentIssue false

Is it important to define skin sub-volumes in breast brachytherapy?

Published online by Cambridge University Press:  02 October 2020

Tabassum Wadasadawala*
Affiliation:
Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
Sabheen Bushra
Affiliation:
Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
Lavanya Gurram
Affiliation:
Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
Libin Scaria
Affiliation:
Department of Medical Physics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
Reena Phurailatpam
Affiliation:
Department of Medical Physics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
Pallavi Rane
Affiliation:
Department of Medical Statistics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
Rajiv Sarin
Affiliation:
Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
*
Author for correspondence: Dr Tabassum Wadasadawala, Department of Radiation Oncology, Advanced Center for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, CISF Road, Near Central Park, Kharghar, Navi Mumbai410210, India. Tel: +91 22 27405079. Fax: +91 22 27405061. E-mail: twadasadawala@actrec.gov.in, drtabassum2004@rediffmail.com

Abstract

Aim:

To evaluate clinically pertinent skin dose and volume parameters for the development of toxicities following accelerated partial breast irradiation (APBI).

Methods:

Three skin structures of various thicknesses inside the body (2 mm, 3 mm, 4 mm) were contoured over the treated breast retrospectively in a cohort of 62 women who underwent APBI using multi-catheter interstitial brachytherapy. The correlation statistics between the various skin structures and acute and late skin sequelae were evaluated using the Mann–Whitney U test and receiver-operating characteristic analysis. A p-value of <0·05 was considered significant.

Results:

At a median follow-up period of 54 months (range: 28–86), a significant correlation was seen between dose received by 0·2 (D0·2) cc of skin 4 mm inside the body as well as volume receiving 100% dose (V100) of skin 3 mm inside the body with cosmesis at 2 years and at last follow-up. The threshold for the two parameters for prediction of excellent or good cosmesis was 90% of the prescribed dose and 0·05 cc, respectively. No significant dosimetric or volumetric correlation was seen with other sequelae like wound dehiscence, fat necrosis, telangiectasia and atrophy.

Conclusion:

The results of this study support the use of dose and volumetric indices of the sub-volumes of the skin for correlation with clinical endpoints. However, the same should be validated prospectively in a larger cohort of women undergoing breast brachytherapy.

Type
Original Article
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Strnad, V, Ott, O J, Hildebrandt, G et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 387: 229238.CrossRefGoogle ScholarPubMed
Antonucci, J V, Wallace, M, Goldstein, N S et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys 2009; 74: 447452.CrossRefGoogle ScholarPubMed
Ott, O J, Strnad, V, Hildebrandt, G et al. GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiother Oncol 2016; 120: 119123.CrossRefGoogle ScholarPubMed
Polgár, C, Ott, O J, Hildebrandt, G et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 259268.CrossRefGoogle ScholarPubMed
Vargo, J A, Verma, V, Kim, H et al. Extended (5-year) outcomes of accelerated partial breast irradiation using MammoSite balloon brachytherapy: patterns of failure, patient selection, and dosimetric correlates for late toxicity. Int J Radiat Oncol Biol Phys 2014; 88: 285291.CrossRefGoogle ScholarPubMed
Shaitelman, S F, Amendola, B, Khan, A et al. American Brachytherapy Society Task Group Report: long-term control and toxicity with brachytherapy for localized breast cancer. Brachytherapy 2017; 16: 1321.CrossRefGoogle ScholarPubMed
Viswanathan, A N, Beriwal, S, Jennifer, F et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 2012; 11: 4752.CrossRefGoogle ScholarPubMed
Strnad, V, Major, T, Polgar, C et al. ESTRO-ACROP guideline: interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost–GEC-ESTRO Breast Cancer Working Group practical recommendations. Radiother Oncol 2018; 128: 411420.CrossRefGoogle ScholarPubMed
Hilts, M, Halperin, H, Morton, D et al. Skin dose in breast brachytherapy: defining a robust metric. Brachytherapy 2015; 14: 970978.CrossRefGoogle ScholarPubMed
Kim, Y, Trombetta, M G. Objective method to report planner-independent skin/rib maximal dose in balloon-based high dose rate (HDR) brachytherapy for breast cancer. Med Phys 2011; 38: 20532057.CrossRefGoogle ScholarPubMed
Rivard, M J, Coursey, B M, DeWerd, L A et al. Update of AAPM Task Group No. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 633674.CrossRefGoogle ScholarPubMed
Gurram, L, Wadasadawala, T, Joshi, K et al. Multi-catheter interstitial brachytherapy for partial breast irradiation: an audit of implant quality based on dosimetric evaluation comparing intra-operative versus post-operative placement. J Contemp Brachytherapy 2016; 8: 116121.CrossRefGoogle ScholarPubMed
Cox, J D, Stetz, J, Pajak, T F. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:13411346.CrossRefGoogle Scholar
Bear, H D, Anderson, S, Brown, A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 41654174.CrossRefGoogle ScholarPubMed
Major, T, Niehoff, P, Kovács, G et al. Dosimetric comparisons between high dose rate interstitial and MammoSite™ balloon brachytherapy for breast cancer. Radiother Oncol 2006; 79: 321328.CrossRefGoogle Scholar
Huang, S Y, Boone, J M, Yang, K et al. The effect of skin thickness determined using breast CT on mammographic dosimetry. Med Phys 2008; 35: 11991206.CrossRefGoogle ScholarPubMed